Clinical trials: Repeated Vaccination
Influenza
Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00538473
- Testing
- GSK Biologicals' influenza vaccine GSK576389A, Fluarix™
- Where
- Belgium
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures
The aims of this vaccine trial are: (1) to measure humoral and selected cellular immune responses to repeated influenza vaccination with Flublok, including these responses' associations with age, birth year, and prior vaccination…
- Trial name
- DRIVE (NCT04576377)
- Testing
- FluBlok
- Where
- Hong Kong
- Volunteers
- 977 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Influenza
Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel
This randomized, open-label, active-controlled trial will assess humoral immune responses to a single dose of 2019-20 recombinant hemagglutinin quadrivalent influenza vaccines (RIV4) compared with standard egg-based unadjuvanted…
- Trial name
- NCT04523324
- Testing
- Flublok™ Quadrivalent by Sanofi, Inc., VaxigripTetra™ by Sanofi, Inc.
- Where
- 2 sites in Israel
- Volunteers
- 577 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Influenza Vaccination, Older Adults (65 Years and Older)
Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults
The goal of this clinical trial is to compare immune responses to different influenza vaccine formulations in older adults and to understand how immune aging and repeated annual influenza vaccination affect these responses.
- Conditions
- Influenza Vaccination, Older Adults (65 Years and Older), Immunosenescence, Immunogenicity
- Trial name
- NCT07838298
- Testing
- Standard dose influenza vaccine, MF59 adjuvanted influenza vaccine, High dose influenza vaccine
- Where
- South Korea
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Influenza, Human, SARS-CoV-2 Infection
Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection
The objectives of this study are to understand the long-term consequences of repeated annual influenza vaccination among healthcare workers (HCWs) and to use statistical and mathematical modelling to elucidate the immunological…
- Trial name
- NCT05110911
- Testing
- Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad, SARS-CoV-2 vaccination: Comirnaty or Vaxzevria
- Where
- 6 sites in Australia
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Influenza
The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study
This study will provide novel insight into the effects of repeat influenza vaccination with Flublok and FluMist on the strength and breadth of immune responses to influenza, the mechanisms underlying heterogeneity in vaccine…
- Trial name
- DRIVE III (NCT07240922)
- Testing
- Live attenuated influenza vaccine, recombinant hemagglutinin influenza vaccine
- Where
- Hong Kong
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Influenza
Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses
The purpose of this study is to assess in healthy subjects the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses of CR8020, a monoclonal antibody against influenza A viruses.
- Trial name
- NCT01756950
- Testing
- 2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Vaccine Response Impaired
Antibodies in Repeated Influenza Vaccination (ARIVA) Study
Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maximally diversify the antibody…
- Trial name
- ARIVA (NCT04059991)
- Testing
- Influenza Vaccination
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Influenza
Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00538213
- Testing
- Fluarix™, GSK Bio's Influenza Vaccine GSK576389A
- Where
- Belgium
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Immunization
Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants
Real-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase vaccination coverage.
- Trial name
- Vakzimeter FLU (NCT06800885)
- Where
- Germany
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
This is a prospective pilot study designed to suggest differences in the immunologic response to the seasonal influenza vaccine in people with regular vaccination history compared to those vaccinated less regularly.
- Trial name
- FLU1 (NCT02876159)
- Testing
- 2016-2017 Influenza Vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Emory University
Respiratory Syncytial Virus Infections
A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of a single intramuscular dose of the investigational respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine during subsequent…
- Trial name
- NCT05229068
- Testing
- RSV MAT
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Yellow Fever
Booster Vaccine for Yellow Fever
This is a phase III trial on Children. The investigators will enroll a total of 750 participants in Fajikunda Health Center (Gambia) The aims of the study are To describe the safety and immunogenicity of a booster dose of a…
- Trial name
- BoVY (NCT05332197)
- Testing
- 17D Yellow fever vaccine
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Influenza
Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00529516
- Testing
- Fluarix, GSK Biologicals Influenza Vaccine GSK576389A
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 1,252 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Immunization
Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants
In June 2024, the German Standing Committee on Vaccination (STIKO) recommended the universal immunization of infants with nirsevimab during their first RSV season.
- Trial name
- Vakzimeter RSV (NCT06824207)
- Where
- Germany
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company